Micronized Progesterone and Epistaxis
Micronized progesterone is not listed as a cause of nosebleeds in FDA labeling, and there is no established causal relationship between progesterone therapy and epistaxis in the medical literature.
Evidence from FDA Drug Labeling
The FDA label for oral micronized progesterone does not include epistaxis (nosebleed) among its adverse reactions 1. The comprehensive adverse event profile from clinical trials and postmarketing surveillance lists numerous side effects including:
- Common reactions (≥2%): headache, breast tenderness, dizziness, abdominal bloating, nausea/vomiting, depression
- Postmarketing cardiovascular events: hypertension, hypotension, circulatory collapse
- Other reported effects: various gastrointestinal, neurological, and dermatological reactions
Notably absent from this extensive list is any mention of epistaxis or bleeding disorders 1.
Context from Epistaxis Guidelines
The 2020 American Academy of Otolaryngology guidelines on epistaxis identify specific medication-related risk factors for nosebleeds 2:
- Anticoagulants (15% of hospitalized epistaxis patients)
- Antiplatelet medications
- New-generation anticoagulants (specifically noted as increasing risk)
Progesterone is not mentioned among medications that increase epistaxis risk, despite the guideline's comprehensive review of systemic factors contributing to nosebleeds 2.
Paradoxical Evidence: Progesterone May Actually Help Epistaxis
Interestingly, there is evidence suggesting progesterone may be therapeutic rather than causative for certain bleeding conditions:
- Low-dose estrogen-progesterone combinations showed benefit in controlling epistaxis in patients with hereditary hemorrhagic telangiectasia (HHT) 3
- This represents the opposite effect of what the question suggests
Clinical Bottom Line
If a patient on micronized progesterone develops epistaxis, look for alternative explanations:
- Age-related factors (bimodal distribution: children <10 years and adults 70-79 years) 2
- Concurrent anticoagulation or antiplatelet therapy
- Hypertension (present in 33% of epistaxis patients, though causality unclear) 2
- Local nasal factors: trauma, dryness, inflammation, septal deviation
- Underlying bleeding disorders: von Willebrand disease, hemophilia, coagulopathy 2
The temporal association between starting progesterone and developing nosebleeds is likely coincidental rather than causal, based on the absence of this adverse effect in FDA surveillance data and clinical trial experience.